SBFM

SBFM

USD

Sunshine Biopharma Inc. Common Stock

$1.730+0.080 (4.848%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.650

高値

$1.730

安値

$1.650

出来高

0.07M

企業ファンダメンタルズ

時価総額

8.5M

業種

Drug Manufacturers - Specialty & Generic

United States

取引統計

平均出来高

0.73M

取引所

NCM

通貨

USD

52週レンジ

安値 $1.169現在値 $1.730高値 $3.9

関連ニュース

AccessWire

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma is quickly establishing which side of that line it's on. After

もっと見る
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
AccessWire

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. , a leading pharmaceutical company focused on innovative and affordable healthcare solutions,

もっと見る
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
AccessWire

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and cash quickly. A lean

もっと見る
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
AccessWire

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to the giants of

もっと見る
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Analyst Upgrades

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma with a Buy and maintains $7 price target.

もっと見る
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target